GlassScriptPhysician profile
Abhishek Singh
NPI 1285366807
$2,746.95
in general payments reported to CMS, 2019-2025
25 companies · $923 in 2025
The $923 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $505 · 2023: $716 · 2024: $603 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,149.23 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $551.94 | 2023-2025 | Qulipta, Avycaz, Rinvoq |
| Astrazeneca Pharmaceuticals LP | $304.52 | 2022-2025 | Farxiga, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $299.72 | 2022-2025 | Opdivo, Camzyos |
| Janssen Biotech, INC. | $242.99 | 2025 | Carvykti, Rybrevant, Talvey |
| Grifols USA, LLC | $236.93 | 2024 | Gamunex-C |
| Bayer Healthcare Pharmaceuticals INC. | $165.99 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $122.68 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $121.17 | 2023 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $96.95 | 2023-2024 | Entyvio |
| Alexion Pharmaceuticals, INC. | $77.96 | 2022-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $72.39 | 2022-2025 | Nucala, Trelegy Ellipta |
| Alnylam Pharmaceuticals INC. | $64.16 | 2025 | Onpattro |
| Amgen INC. | $49.73 | 2025 | Blincyto |
| Fresenius Kabi USA, LLC | $48.04 | 2025 | |
| Pfizer INC. | $42.47 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.28 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $34.70 | 2024 | Keytruda |
| Seagen INC. | $29.96 | 2022 | |
| Incyte Corporation | $29.46 | 2025 | Niktimvo |
| Geron Corporation | $24.30 | 2025 | Rytelo |
| Lilly USA, LLC | $22.25 | 2024 | Zepbound, Jardiance |
| Actelion Pharmaceuticals US, INC. | $19.05 | 2025 | Opsumit |
| Karyopharm Therapeutics INC. | $18.44 | 2024 | Xpovio |
| Alcresta Therapeutics, INC. | $16.36 | 2023 | Relizorb |
| Janssen Pharmaceuticals, INC | $15.51 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhishek Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.